Please login to the form below
Merck and Co.
This page shows the latest Merck and Co. news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s mild combination asthma reliever approved in UK
Asthma is a chronic, variable, inflammatory disease characterised by asthma attacks and symptoms including breathlessness and wheezing. ... The authorisation comes just days after AZ and MSD’s – known as Merck &Co in the US and Canada – Lynparza
Latest news
-
AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
AstraZeneca and MSD's – known as Merck &Co in the US and Canada – Lynparza (olaparib) has been approved in the UK as part of a combination therapy for certain prostate cancer ... a range of indications for ovarian, breast, fallopian tube, peritoneal
-
AstraZeneca and MSD report final overall survival results from prostate cancer study
AstraZeneca and MSD – known as Merck &Co in the US and Canada – have reported final overall survival results from a phase 3 trial of a Lynparza (olaparib) combination in metastatic ... The drug also holds a number of approvals for a range of
-
MSD’s Keytruda plus chemotherapy approved in Scotland for advanced cervical cancer
There were around 604, 000 new cases and 342, 000 deaths in 2020 from cervical cancer. ... MSD’s – known as Merck &Co in the US and Canada – Keytruda (pembrolizumab) in combination with chemotherapy has been recommended by the Scottish Medicines
-
Moderna to acquire OriCiro Genomics for $85m
In December 2022, a personalised mRNA cancer vaccine from Moderna and Merck &Co – known as MSD outside the US and Canada – was shown to benefit patients with high-risk melanoma. ... In October 2022, the companies announced that Merck had exercised
-
AZ and MSD launch ‘Never Miss’ for prostate cancer awareness
A new prostate cancer awareness campaign titled‘Never Miss’ has been launched by AstraZeneca (AZ) in partnership with MSD – known as Merck &Co in the US and Canada. ... also supporting them in feeling able to speak openly with family and friends.
More from news
Approximately 44 fully matching, plus 527 partially matching documents found.
Latest Intelligence
-
Envisioning a healthier every day, for every woman
By Sandy Lindsey. It’s little over a year since the bell first rang on the New York Stock Exchange announcing the arrival of Organon &Co, a spin-off from MSD ... known as Merck &Co in the US and Canada) with a mission to create improved health outcomes
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Similarly, Novartis formed the investment firm Novartis Venture Funds and Merck &Co. ... created the Merck Research Venture Fund. Nowadays, having a venture arm to proactively research for outside R&D sourcing is common for most mid- to large- sized
-
AI: the smart money is on the smart thinking
Bayer and Merck &Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form ... Bayer and Merck &Co hope that radiologists
-
Can protein degraders unlock ‘undruggable’ drug targets?
like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.
-
Vertex: a vision of treating all CF patients worldwide draws closer
Ex-Merck &Co. scientist Joshua Boger did want the company to pioneer rationale drug discovery and development, however, and after. ... a loss in almost all of its 20+ years, and has cumulative net losses of around $3bn.
More from intelligence
Approximately 0 fully matching, plus 45 partially matching documents found.
Latest appointments
-
Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
Arnhofer joins the agency with two decades of experience in the biopharma industry, having held a variety of senior positions at Merck &Co, Bayer AG and BioNTech SE. ... Storyteq marketing collaboration and creative automation platform, in addition to
-
Merck & Co appoints Frank Clyburn as president, human health
Merck &Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health. ... Clyburn joined Merck &Co in 2008 and during his time with the company, he has had responsibility for various global
-
Weekly industry appointments
Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.
-
Nabriva Therapeutics appoints chief medical officer
Schranz. Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.
-
Hansa Medical poaches Vifor Pharma’s CEO
Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in
More from appointments
Approximately 4 fully matching, plus 35 partially matching documents found.
Latest from PMHub
-
Practical Patient Centricity
Merck &Co, Sanofi and UCB have identified the competitive advantage that patient centricity brings and are leading the way in its practical implementation. ... Patient centricity is the next market access – and will take 10 years to embed”.
-
Digital Marketing is no Substitute for Sound Strategic Marketing
With a stronger market access focus, companies can create and implement stronger marketing strategies. ... With no prior blueprint on how to ‘go digital’ in their marketing, early pioneer companies such as Merck &Co.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- PMGroup announces launch of new recruitment platform PharmaRole
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- BioNTech reveals plans to spend about €1bn more on research and development this year
- AstraZeneca’s mild combination asthma reliever approved in UK
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Inizio appoints Stefanie Christmas as global head of DE&I
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
